Beta Bionics, Inc. (Nasdaq: BBNX) reported its preliminary, unaudited topline financial results for the fourth quarter of 2025, showcasing significant growth in net sales and key metrics.
The company highlighted the performance of its Durable Medical Equipment (DME) and Pharmacy Benefit Plan (PBP) channels, along with an increase in the installed customer base and new patient starts.
Beta Bionics invited investors to in-person meetings to discuss the financial results and metrics.
Net Sales Growth
Net sales expected to be at least $32.0 million, reflecting a 56% increase compared to the same quarter in 2024.
Customer Base Expansion
Installed customer base anticipated to reach at least 35,000 users, marking a 128% increase from the fourth quarter of 2024.
New Patients Increase
New patient starts projected to be at least 5,581, showing a 36% rise compared to the previous year.
- The substantial growth in net sales indicates strong market demand and customer adoption of Beta Bionics' diabetes management solutions.
- The increase in the customer base and new patient starts demonstrates the company's ability to attract and retain users, showcasing the effectiveness of its products and services.
Beta Bionics' preliminary fourth quarter 2025 results reflect a positive trajectory in financial performance and customer acquisition. The company's innovative solutions continue to resonate with the market, driving growth and enhancing the quality of life for insulin-requiring individuals.